

# Michael Froehner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5298119/publications.pdf>

Version: 2024-02-01

105  
papers

1,635  
citations

361413

20  
h-index

345221

36  
g-index

105  
all docs

105  
docs citations

105  
times ranked

2476  
citing authors

#	ARTICLE	IF	CITATIONS
1	Urinary MicroRNAs as Potential Markers for Non-Invasive Diagnosis of Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3814.	4.1	15
2	ProstaTrendâ€”A Multivariable Prognostic RNA Expression Score for Aggressive Prostate Cancer. <i>European Urology</i> , 2020, 78, 452-459.	1.9	15
3	[68Ga]Ga-PSMA-11 PET before and after initial long-term androgen deprivation in patients with newly diagnosed prostate cancer: a retrospective single-center study. <i>EJNMMI Research</i> , 2020, 10, 135.	2.5	11
4	Evaluation of Transperineal Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy Compared to Transrectal Systematic Biopsy in the Prediction of Tumour Aggressiveness in Patients with Previously Negative Biopsy. <i>Urologia Internationalis</i> , 2019, 102, 20-26.	1.3	6
5	Long-Term Mortality in Patients with Positive Lymph Nodes at the Time of Radical Prostatectomy. <i>Urologia Internationalis</i> , 2019, 103, 427-432.	1.3	6
6	â€”68Ga-RM2 PET in PSMA- positive and -negative prostate cancer patients. <i>Nuklearmedizin - NuclearMedicine</i> , 2019, 58, 352-362.	0.7	9
7	Re: Sebastian Berg, Alexander P. Cole, Marieke J. Krimphove, et al. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. <i>Eur Urol</i> 2019;75:552â€”5. <i>European Urology</i> , 2019, 76, e75.	1.9	0
8	Evaluation of TERT promoter mutations in urinary cell-free DNA and sediment DNA for detection of bladder cancer. <i>Clinical Biochemistry</i> , 2019, 64, 60-63.	1.9	36
9	Leiomyosarcoma of the Urinary Bladder in Adult Patients: A Systematic Review of the Literature and Meta-Analysis. <i>Urologia Internationalis</i> , 2019, 102, 96-101.	1.3	11
10	Validation of the Preoperative Score to Predict Postoperative Mortality in Patients Undergoing Radical Cystectomy. <i>European Urology Focus</i> , 2019, 5, 197-200.	3.1	12
11	Only &lt;10% of Patients Selected for Radical Prostatectomy Reach the Competing Mortality Rate of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). <i>European Urology Focus</i> , 2019, 5, 361-364.	3.1	6
12	Evaluation of Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy in Patients with Low-Risk Prostate Cancer Under Active Surveillance Undergoing Surveillance Biopsy. <i>Urologia Internationalis</i> , 2018, 100, 155-163.	1.3	12
13	Chronically Infected Urachal Remnant Mimicking Tumor With Peritoneal Carcinomatosis. <i>Urology</i> , 2018, 116, e3-e4.	1.0	0
14	Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Nodeâ€”Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Scoreâ€”Weighted Competing Risks Analysis. <i>European Urology Focus</i> , 2018, 4, 252-259.	3.1	18
15	Selection Effects May Explain Smoking-related Outcome Differences After Radical Cystectomy. <i>European Urology Focus</i> , 2018, 4, 395-398.	3.1	2
16	Prospective comparison of transperineal magnetic resonance imaging/ultrasonography fusion biopsy and transrectal systematic biopsy in biopsyâ€”naïve patients. <i>BJU International</i> , 2018, 121, 53-60.	2.5	47
17	Surgical resection of locally recurrent renal cell carcinoma after nephrectomy: Oncological outcome and predictors of survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 11.e1-11.e6.	1.6	9
18	Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer Patients. <i>European Urology Oncology</i> , 2018, 1, 91-100.	5.4	46

#	ARTICLE	IF	CITATIONS
19	Predicting 90-day and long-term mortality in octogenarians undergoing radical cystectomy. BMC Urology, 2018, 18, 91.	1.4	12
20	Role of WNT5A receptors FZD5 and RYK in prostate cancer cells. Oncotarget, 2018, 9, 27293-27304.	1.8	27
21	Prostate-specific Membrane Antigen-targeted Ligand Positron Emission Tomography/Computed Tomography and Immunohistochemical Findings in a Patient With Synchronous Metastatic Penile and Prostate Cancer. Urology, 2017, 101, e5-e6.	1.0	11
22	Delayed Radiographic Manifestation of Renal Pseudoaneurysms After Blunt Trauma. Urology, 2017, 103, e9-e10.	1.0	0
23	Testicular cancer patients undergoing cisplatin based chemotherapy exhibit temporary olfactory threshold scores changes. European Archives of Oto-Rhino-Laryngology, 2017, 274, 2813-2818.	1.6	8
24	Urinary transcript quantitation of CK20 and IGF2 for the non-invasive bladder cancer detection. Journal of Cancer Research and Clinical Oncology, 2017, 143, 1757-1769.	2.5	14
25	Predicting Competing Mortality in Patients Undergoing Radical Prostatectomy Aged 70 yr or Older. European Urology, 2017, 71, 710-713.	1.9	12
26	Age and Charlson Score. Annals of Surgical Oncology, 2017, 24, 677-678.	1.5	0
27	PSMA-PET/CT-Positive Paget Disease in a Patient with Newly Diagnosed Prostate Cancer: Imaging and Bone Biopsy Findings. Case Reports in Urology, 2017, 2017, 1-3.	0.3	15
28	Level of education and mortality after radical prostatectomy. Asian Journal of Andrology, 2017, 19, 173.	1.6	5
29	Direct comparison of multiparametric magnetic resonance imaging (<sc>MRI</sc>) results with final histopathology in patients with proven prostate cancer in <sc>MRI</sc>/ultrasonographyâ€fusion biopsy. BJU International, 2016, 118, 213-220.	2.5	68
30	Androgen Deprivation Therapy and Alzheimer's Disease. Journal of Clinical Oncology, 2016, 34, 2801-2801.	1.6	5
31	Re: Jesse D. Sammon, Firas Abdollah, Anthony Dâ€™Amico, et al. Predicting Life Expectancy in Men Diagnosed with Prostate Cancer. Eur Urol 2015;68:756â€75.. European Urology, 2016, 69, e128.	1.9	0
32	Validation of an Age-adjusted Prostate Cancerâ€™Specific Comorbidity Index. European Urology, 2016, 69, 764-766.	1.9	15
33	Splenunculus Masquerading as Prostate-specific Membrane Antigen-positive Lymph Node Metastasis in a Patient With Prostate-specific Antigen Relapse After Radical Prostatectomy. Urology, 2016, 94, e1-e2.	1.0	8
34	Renal Sarcoidosis Mimicking Xanthogranulomatous Pyelonephritis. Urology, 2016, 97, e19-e20.	1.0	4
35	Prediction of cancerâ€™specific survival after radical cystectomy in <sc>pT4a</sc> urothelial carcinoma of the bladder: development of a tool for clinical decisionâ€™making. BJU International, 2016, 117, 272-279.	2.5	29
36	Re: Grace L. Lu-Yao, Peter C. Albertsen, Dirk F. Moore, Yong Lin, Robert S. DiPaola, Siu-Long Yao. Fifteen-year Outcomes Following Conservative Management Among Men aged 65 Years or Older with Localized Prostate Cancer. Eur Urol 2015;68:805â€811. European Urology, 2016, 69, e130.	1.9	1

#	ARTICLE	IF	CITATIONS
37	Growth of a Level III Vena Cava Tumor Thrombus Within 1 Month. <i>Urology</i> , 2016, 90, e1-e2.	1.0	16
38	Age, American Society of Anesthesiologists physical status classification and Charlson score are independent predictors of 90-day mortality after radical cystectomy. <i>World Journal of Urology</i> , 2016, 34, 1123-1129.	2.2	21
39	Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. <i>Eur Urol</i> 2016;70:21â€“30. <i>European Urology</i> , 2016, 70, e9.	1.9	0
40	Decreased Overall and Bladder Cancerâ€“Specific Mortality with Adjuvant Chemotherapy After Radical Cystectomy: Multivariable Competing Risk Analysis. <i>European Urology</i> , 2016, 69, 984-987.	1.9	27
41	Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer. <i>European Urology</i> , 2015, 67, 460-467.	1.9	190
42	Prostate-specific Antigen Pox Virus Vaccination for Recurrent Prostate Cancer. <i>European Urology</i> , 2015, 68, 372-373.	1.9	0
43	Should the Urologist Treat Castration Resistant Prostate Cancer?. <i>Journal of Urology</i> , 2015, 194, 286-286.	0.4	1
44	Integrated prostate cancer centers might cause an overutilization of radiotherapy for low-risk prostate cancer: A comparison of treatment trends in the United States and Germany from 2004 to 2011. <i>Radiotherapy and Oncology</i> , 2015, 115, 90-95.	0.6	29
45	Re: Syed Johar Raza, Timothy Wilson, James O. Peabody, et al. Long-term Oncologic Outcomes Following Robot-assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. <i>Eur Urol</i> 2015;68:721â€“8. <i>European Urology</i> , 2015, 68, e109.	1.9	2
46	Re: Malte Rieken, Shahrokh F. Shariat, Luis A. Kluth, et al. Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy. <i>Eur Urol</i> . In press. <a href="http://dx.doi.org/10.1016/j.eururo.2015.05.038">http://dx.doi.org/10.1016/j.eururo.2015.05.038</a> . <i>European Urology</i> , 2015, 68, e103.	1.9	2
47	Re: Firas Abdollah, Giorgio Gandaglia, Nazareno Suardi, et al. More Extensive Pelvic Lymph Node Dissection Improves Survival in Patients with Node-positive Prostate Cancer. <i>Eur Urol</i> 2015;67:212â€“9. <i>European Urology</i> , 2015, 67, e112.	1.9	1
48	Simultaneous Targeting of the Akt and Androgen Receptor Pathways. <i>European Urology</i> , 2015, 67, 991-992.	1.9	0
49	Approaches to radical prostatectomy. <i>Journal of Comparative Effectiveness Research</i> , 2014, 3, 451-453.	1.4	1
50	Charlson score and competing mortality. <i>Cancer</i> , 2014, 120, 4003-4003.	4.1	1
51	A combined index to classify prognostic comorbidity in candidates for radical prostatectomy. <i>BMC Urology</i> , 2014, 14, 28.	1.4	20
52	Treatment of Bone Metastases in Urologic Malignancies. <i>Urologia Internationalis</i> , 2014, 93, 249-256.	1.3	18
53	Re: Atiqullah Aziz, Matthias May, Maximilian Burger, et al. PROMETRICS 2011 research group. Prediction of 90-day Mortality After Radical Cystectomy for Bladder Cancer in a Prospective European Multicenter Cohort. <i>Eur Urol</i> 2014;66:156â€“163. <i>European Urology</i> , 2014, 66, e13.	1.9	3
54	Adult inguinoscrotal sarcomas: outcome analysis of 21 cases, systematic review of the literature and meta-analysis. <i>World Journal of Urology</i> , 2014, 32, 445-451.	2.2	11

#	ARTICLE	IF	CITATIONS
55	Socio-economic deprivation and cancer survival in Germany. <i>International Journal of Cancer</i> , 2014, 135, 1989-1989.	5.1	0
56	Relationship of the Number of Removed Lymph Nodes to Bladder Cancer and Competing Mortality After Radical Cystectomy. <i>European Urology</i> , 2014, 66, 987-990.	1.9	34
57	Testing of a Novel Easy-to-use Mortality Index in a Radical Prostatectomy Cohort. <i>Urology</i> , 2014, 84, 307-313.	1.0	3
58	Reply. <i>Urology</i> , 2014, 84, 312-313.	1.0	2
59	Re: Zhu et al.: The Expression and Evaluation of Androgen Receptor in Human Renal Cell Carcinoma ( <i>Urology</i> 2014;83:510.e19-24). <i>Urology</i> , 2014, 84, 734-735.	1.0	2
60	Re: Kenneth G. Nepple, Andrew J. Stephenson, Dorina Kallogjeri, et al. Mortality After Prostate Cancer Treatment with Radical Prostatectomy, External-Beam Radiation Therapy, or Brachytherapy in Men Without Comorbidity. <i>Eur Urol</i> 2013;64:372-8. <i>European Urology</i> , 2014, 65, e41.	1.9	0
61	Does increasing life expectancy affect competing mortality after radical prostatectomy?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 413-418.	1.6	8
62	Re: Karim A. Touijer, Clarisse R. Mazzola, Daniel D. Sjoberg, Peter T. Scardino, James A. Eastham. Long-term Outcomes of Patients with Lymph Node Metastasis Treated with Radical Prostatectomy Without Adjuvant Androgen-deprivation Therapy. <i>Eur Urol</i> 2014;65:20-5. <i>European Urology</i> , 2014, 65, e24.	1.9	1
63	Re: Jim C. Hu, Giorgio Gandaglia, Pierre I. Karakiewicz, et al. Comparative Effectiveness of Robot-assisted Versus Open Radical Prostatectomy Cancer Control. <i>Eur Urol</i> 2014;66:666-72. <i>European Urology</i> , 2014, 66, e85.	1.9	2
64	Predictive Significance of Confirmation Biopsies in Patients on Active Surveillance. <i>European Urology</i> , 2014, 66, 414-415.	1.9	0
65	In Regard to Nanda et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 431.	0.8	3
66	Re: Robot-Assisted versus Open Radical Prostatectomy: The Differential Effect of Regionalization, Procedure Volume and Operative Approach. <i>Journal of Urology</i> , 2013, 190, 1440-1441.	0.4	0
67	Adult urologic sarcoma: Experience during 2 decades. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 985-989.	1.6	8
68	Locally Advanced Prostate Cancer: Optimal Therapy in Older Patients. <i>Drugs and Aging</i> , 2013, 30, 959-967.	2.7	3
69	Urinary Tract-Related Quality of Life after Radical Prostatectomy: Open Retropubic versus Robot-Assisted Laparoscopic Approach. <i>Urologia Internationalis</i> , 2013, 90, 36-40.	1.3	28
70	Prostate-specific Antigen-negative Prostate Cancer Recurrence?. <i>Urology</i> , 2013, 81, e17-e18.	1.0	4
71	Which comorbidity classification best fits elderly candidates for radical prostatectomy?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 461-467.	1.6	14
72	Perioperative Complications after Radical Prostatectomy: Open versus Robot-Assisted Laparoscopic Approach. <i>Urologia Internationalis</i> , 2013, 90, 312-315.	1.3	42

#	ARTICLE	IF	CITATIONS
73	Screening and efficacy of radical prostatectomy. Asian Journal of Andrology, 2013, 15, 441-442.	1.6	0
74	Comorbidity and survival of patients selected for radical prostatectomy at an age of 75 years or older. Asian Journal of Andrology, 2013, 15, 667-671.	1.6	2
75	Competing Mortality Contributes to Excess Mortality in Patients with Poor-Risk Lymph Node-Positive Prostate Cancer Treated with Radical Prostatectomy. Urologia Internationalis, 2012, 89, 148-154.	1.3	7
76	Re: Association of Androgen Deprivation Therapy with Cardiovascular Death in Patients with Prostate Cancer: A Meta-Analysis of Randomized Trials. European Urology, 2012, 62, 350.	1.9	1
77	Which patients are at the highest risk of dying from competing causes 10 years after radical prostatectomy?. BJU International, 2012, 110, 206-210.	2.5	24
78	Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer, 2011, 117, 2577-2577.	4.1	6
79	Response to "Predictors of Prostate Cancer-Specific Mortality in Elderly Men With Intermediate-Risk Prostate Cancer Treated With Brachytherapy With or Without External Beam Radiation Therapy" (Int J Tj ETQq1 1 0,784314 rgBT /Qv 2010, 76, 1274.	0.8	1
80	Survival analysis in men undergoing radical prostatectomy at an age of 70 years or older. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 628-634.	1.6	10
81	Complications Following Radical Cystectomy for Bladder Cancer in the Elderly. European Urology, 2009, 56, 443-454.	1.9	242
82	Derivatives of prostate-specific antigen as predictors of incidental prostate cancer. BJU International, 2009, 104, 25-28.	2.5	11
83	Nomogram Underestimates 10-year Survival in Healthy Men Selected for Radical Prostatectomy at Age 70 Years or Older. Urology, 2009, 73, 610-613.	1.0	11
84	Second Cancers as Competing Causes of Death After Radical Prostatectomy. Journal of Urology, 2009, 182, 967-971.	0.4	10
85	Detailed Analysis of Charlson Comorbidity Score as Predictor of Mortality After Radical Prostatectomy. Urology, 2008, 72, 1252-1257.	1.0	34
86	Interaction Between Age and Comorbidity as Predictors of Mortality After Radical Prostatectomy. Journal of Urology, 2008, 179, 1823-1829.	0.4	15
87	Successful Chemotherapy for Advanced Nonseminomatous Germ-Cell Tumor in a Patient Undergoing Chronic Hemodialysis. Journal of Clinical Oncology, 2007, 25, 1282-1284.	1.6	8
88	Molecular Therapy in Urologic Oncology. Urologia Internationalis, 2007, 79, 1-7.	1.3	20
89	Changing comorbidity classification patterns at radical prostatectomy during a 10-year period. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 26-31.	1.6	3
90	Magnetic resonance imaging of bone metastases in patients with nonseminomatous germ cell tumors. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 201-206.	1.6	5

#	ARTICLE	IF	CITATIONS
91	Comorbidity is poor predictor of survival in patients undergoing radical prostatectomy after 70 years of age. <i>Urology</i> , 2006, 68, 583-586.	1.0	14
92	11C-Acetate positron emission tomography for occult prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006, 24, 410-411.	1.6	5
93	Lack of efficacy of imatinib in a patient with metastatic Leydig cell tumor. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 716-718.	2.3	17
94	Comparison of the Clinical Value of Complexed PSA and Total PSA in the Discrimination between Benign Prostatic Hyperplasia and Prostate Cancer. <i>Urologia Internationalis</i> , 2006, 76, 27-30.	1.3	14
95	Feasibility and Limitations of Comorbidity Measurement in Patients Undergoing Radical Prostatectomy. <i>European Urology</i> , 2005, 47, 190-195.	1.9	26
96	Comparison of tumor- and comorbidity-related predictors of mortality after radical prostatectomy. <i>Scandinavian Journal of Urology and Nephrology</i> , 2005, 39, 449-454.	1.4	6
97	Renal staghorn calculus?. <i>Urology</i> , 2005, 65, 171.	1.0	0
98	Gastrointestinal stromal tumor presenting as a scrotal mass. <i>International Journal of Urology</i> , 2004, 11, 445-447.	1.0	10
99	Which Conditions Contributing to the Charlson Score Predict Survival After Radical Prostatectomy?. <i>Journal of Urology</i> , 2004, 171, 697-699.	0.4	23
100	Urinary immunocytology for primary bladder B cell lymphoma. <i>Urology</i> , 2004, 63, 381-383.	1.0	9
101	Adult prostate sarcoma diagnosed from tissue spontaneously excreted through the urethra. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2004, 22, 119-120.	1.6	11
102	Preoperative cardiopulmonary risk assessment as predictor of early noncancer and overall mortality after radical prostatectomy. <i>Urology</i> , 2003, 61, 596-600.	1.0	26
103	Malignant fibrous histiocytoma masquerading as germ cell tumor by producing beta-human chorionic gonadotropin and neuron-specific enolase. <i>Urology</i> , 2003, 62, 551.	1.0	1
104	Comparison of the American Society of Anesthesiologists Physical Status classification with the Charlson score as predictors of survival after radical prostatectomy. <i>Urology</i> , 2003, 62, 698-701.	1.0	70
105	The Management of Localized or Locally Advanced Prostate Cancer. <i>American Journal of Cancer</i> , 2002, 1, 387-396.	0.4	1